Femara marks new territory

Researchers from Novartis AG reinforced the ability of pharmacogenomics to identify the non-obvious last week, as they presented data showing that Femara letrozole was more efficient than tamoxifen in treating breast cancer patients whose disease is characterized as estrogen receptor-positive (ER+) plus ErbB1

Read the full 438 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE